cytarabine has been researched along with hydrazine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (31.82) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 6 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Cozzarelli, NR | 1 |
| Schöneich, J; Wobus, AM | 1 |
| Inoue, H; Kishimoto, T; Miyake, T; Nishizawa, Y; Watanabe, T | 1 |
| Bernard, J; Blom, J; Boiron, M; Brunner, K; Cooper, MR; Cuttner, J; Ellison, RR; Gailani, S; Glidewell, OJ; Haurani, F; Holland, JF; Hoogstraten, B; Jacquillat, C; Levy, R; Lowenstein, L; Nissen, NI; Rege, VB; Serpick, AA; Silver, RT; Wasserman, L; Weil, M; Wiernik, PH | 1 |
| Brunner, KW | 1 |
| Nixon, DD; Ultmann, JE | 1 |
| Mihich, E; Mulhern, AI | 1 |
| Albitar, M; Cahill, A; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Gerson, S; Giles, F; Jabbour, E; Kantarjian, H; Karsten, V; Kornblau, S; O'Brien, S; Ravandi, F; Sznol, M; Thomas, D; Verstovsek, S; Yee, K | 1 |
| Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Adams, JA; Liu Yin, JA; Morris, KL | 1 |
| Giles, FJ | 1 |
| Albitar, M; Boskovic, D; Brandwein, J; Cahill, A; DeAngelo, D; Giles, F; Kell, J; O'Brien, S; Pigneux, A; Robak, T; Seiter, K; Staib, P; Stock, W; Stuart, R; Tallman, M; Thomas, X; Vey, N | 1 |
| Chen, H; Deisseroth, A; Farrell, A; He, K; Justice, R; Kane, R; Pazdur, R; Sridhara, R | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Dama, P; Fulton, N; Kline, J; Liu, H; Tang, M | 1 |
| Chavez, J; Cubitt, CL; Dawson, JL; Komrokji, R; Lancet, JE; List, AF; Padron, E; Sallman, DA; Shah, BD; Sullivan, DM; Sweet, K; Turner, JG; Zhou, J | 1 |
| Abboud, CN; Abboud, R; Chendamarai, E; DiPersio, JF; Ghobadi, A; Pusic, I; Rettig, MP; Riedell, PA; Schroeder, MA; Stockerl-Goldstein, K; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
| Cerny, J; Lazarus, HM; Litzow, M; Rowe, JM; Rybka, W; Strickland, SA; Tallman, MS; Wang, XV | 1 |
| Amberg, S; Bokemeyer, C; Christine Wilke, A; Chromik, J; Deppermann, U; Fiedler, W; Ganser, A; Heuser, M; Janning, M; Kebenko, M; Kranich, AL; Modemann, F; Schlipfenbacher, V; Serve, H; Theile, S; Thol, F | 1 |
| Acuña-Cruz, E; Barragán, E; Bergua, JM; Boluda, B; Cano-Ferri, I; Martín-Herreros, B; Martínez Sánchez, MP; Martínez-Cuadrón, D; Martínez-López, J; Megías-Vericat, JE; Montesinos, P; Rodríguez-Veiga, R; Sanz, M; Sargas, C; Sempere, A; Serrano, A; Suárez-Varela, S; Torrent, A; Torres-Miñana, L; Vives, S | 1 |
| Biemond, BJ; Boersma, RS; Chalandon, Y; de Weerdt, O; Deeren, D; Efthymiou, A; Fehr, M; Graux, C; Gregor, M; Heim, D; Janssen, JJWM; Jongen-Lavrencic, M; Klein, SK; Legdeur, MCJC; Löwenberg, B; Manz, M; Ossenkoppele, GJ; Pabst, T; Sinnige, HAM; Spertini, O; Stüssi, G; Tick, LW; van der Poel, MWM; van Norden, Y; van Obbergh, F; van Sluis, G; Westerweel, PE | 1 |
5 review(s) available for cytarabine and hydrazine
| Article | Year |
|---|---|
The mechanism of action of inhibitors of DNA synthesis.
Topics: Acetates; Animals; Bacillus subtilis; Cytarabine; DNA; DNA Polymerase I; DNA Polymerase II; DNA Polymerase III; DNA Replication; Edeine; Hydrazines; Nalidixic Acid; Novobiocin; Nucleic Acid Synthesis Inhibitors; Organophosphonates; Pyrimidines; Structure-Activity Relationship; Vidarabine; Zinostatin | 1977 |
[Progress in the drug therapy of cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cytarabine; Daunorubicin; Drug Synergism; Humans; Hydrazines; Hydroxyurea; Neoplasms; Nitroso Compounds; Picolinic Acids; Pyrogallol; Quinolines; Streptonigrin; Urea | 1968 |
The therapy of lymphoma.
Topics: Adrenal Cortex Hormones; Asparaginase; Bone Marrow Diseases; Chlorambucil; Cyclophosphamide; Cytarabine; Daunorubicin; Fever; Humans; Hydrazines; Infections; Kidney Failure, Chronic; Lymphoma; Mechlorethamine; Splenectomy; Vinblastine; Vincristine | 1969 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
8 trial(s) available for cytarabine and hydrazine
| Article | Year |
|---|---|
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Topics: Adult; Aged; Alkylating Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Cohort Studies; Cytarabine; Disease Progression; DNA; DNA Repair; Female; Humans; Hydrazines; Leukemia; Leukocytes, Mononuclear; Male; Middle Aged; Models, Chemical; O(6)-Methylguanine-DNA Methyltransferase; Sulfonamides; Time Factors | 2005 |
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Humans; Hydrazines; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sulfonamides; Young Adult | 2009 |
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Drug Resistance, Neoplasm; Female; Galectins; Hepatitis A Virus Cellular Receptor 2; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; T-Lymphocyte Subsets; Treatment Failure; Triazoles | 2019 |
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Patient Safety; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles | 2020 |
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Filgrastim; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Mice, Inbred C57BL; Middle Aged; Remission Induction; Treatment Outcome; Triazoles; Young Adult | 2020 |
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Recurrence; Salvage Therapy; Triazoles | 2020 |
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Triazoles; Vidarabine | 2021 |
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Triazoles | 2022 |
9 other study(ies) available for cytarabine and hydrazine
| Article | Year |
|---|---|
[A cytological test system for the routine determination of mutagenicity].
Topics: Ascitic Fluid; Caffeine; Cells, Cultured; Chromosome Aberrations; Cytarabine; Hydrazines; Isonicotinic Acids; Mechlorethamine; Methods; Mutation; Netropsin | 1977 |
Triggering mechanism of B lymphocytes. II. Induction of ornithine decarboxylase in B cells by anti-immunoglobulin and enhancing soluble factor.
Topics: Animals; Antibodies, Anti-Idiotypic; B-Lymphocytes; Carboxy-Lyases; Cytarabine; Cytochalasin B; Enzyme Induction; Hydrazines; Hydroxyurea; Immunoglobulin Fab Fragments; Immunoglobulins; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitors; Rabbits; T-Lymphocytes; Time Factors | 1975 |
Daunorubicin in the therapy of acute granulocytic leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Platelets; Blood Transfusion; Cytarabine; Daunorubicin; Female; Humans; Hydrazines; Hyperplasia; Leukemia, Myeloid; Leukocyte Count; Leukopenia; Male; Mercaptopurine; Methotrexate; Middle Aged; Remission, Spontaneous; Thrombocytopenia; Time Factors | 1973 |
Effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone) on leukemia L1210.
Topics: Animals; Antineoplastic Agents; Cytarabine; Drug Synergism; Female; Hydrazines; Injections, Intraperitoneal; Injections, Subcutaneous; Leukemia L1210; Male; Mice; Time Factors; Urea | 1968 |
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan | 2008 |
Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Leukemia, Myeloid, Acute; Sulfonamides | 2009 |
Laromustine: the return of alkylators to non-myeloablative therapy of AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Leukemia, Myeloid, Acute; Sulfonamides | 2009 |
Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Humans; Hydrazines; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sulfonamides | 2010 |
A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoates; Consolidation Chemotherapy; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Pyrazoles | 2020 |